FumitoItoMDPhD, FACS
General Surgery • Los Angeles, CABreast, Melanoma, Surgical Oncology (Other than Breast)
Surgical Oncologist, University of Southern California
Dr. Ito is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1450 Biggy St.
Los Angeles, CA 90033
Summary
- Dr. Ito received his MD and a PhD in tumor immunology from the Shiga University of Medical Science, where he also completed his first surgical training. After spending two and a half years studying immunotherapy in a lab setting at the University of Michigan, he completed a second surgical residency at the University of Wisconsin and a fellowship in surgical oncology at the Roswell Park Comprehensive Cancer Center in Buffalo, NY.
After spending four years as a surgeon-scientist at the University of Michigan, Dr. Ito returned to Roswell Park to continue his surgical practice and expand his research in tumor immunology and cancer immunotherapy. Dr. Ito joined Keck Medicine of USC in 2021 as an Associate Professor of Surgery, and serves as Co-Leader of the USC Norris Translational and Clinical Sciences (TACS) Research Program.
Dr. Ito is fascinated by the potential of immunotherapy, and uses his combined expertise in immunology and surgery to offer a range of options and design a unique plan of care for each patient.
Clinical Expertise
- Melanoma and cutaneous malignancies, Breast cancer, Breast surgery, Surgical oncology (non-breast)
Certifications & Licensure
CA State Medical License 2021 - 2025
NY State Medical License 2008 - 2025
MI State Medical License 2010 - 2017
WI State Medical License 2007 - 2011
American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
Publications & Presentations
PubMed
- Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient du...Ryutaro Kajihara, Mark D Long, Toshifumi Hoki, Hongbin Chen, Takayoshi Yamauchi
Journal for Immunotherapy of Cancer. 2025-01-25 - Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24 - 3 citationsGeneration, Transcriptomic States, and Clinical Relevance of CX3CR1+ CD8 T Cells in Melanoma.Hirohito Ishigaki, Takayoshi Yamauchi, Mark D Long, Toshifumi Hoki, Yuta Yamamoto
Cancer Research Communications. 2024-07-01
Press Mentions
USC Team IDs Biomarker for NSCLC Response to ChemoimmunotherapyMay 17th, 2023- Study Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
- USC Research Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
- Join now to see all
Grant Support
- Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy AssayNational Cancer Institute (NCI)2022–2027
- In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors.National Cancer Institute (NCI)2021–2026
Committees
- Co-Leader, USC Translational and Clinical Sciences (TACS) program
Other Languages
- Japanese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
